Causes and consequences of increased arterial stiffness in chronic kidney disease patients.
Cardiovascular (CV) morbidity and mortality is greatly enhanced in patients with chronic kidney disease, compared to the non-renal population. One key element of this high CV burden appears to be arterial stiffness, as an expression of premature vascular aging. Increased arterial stiffness in renal patients may be a consequence of vascular calcification, chronic volume overload, inflammation, endothelial dysfunction, oxidative stress and several other factors. The authors review briefly the main pathophysiological mechanisms leading to reduced arterial compliance. Increased arterial stiffness has significant clinical consequences: isolated systolic hypertension, left ventricular hypertrophy (and failure), and reduced myocardial perfusion. Better knowledge of the mechanisms of arterial functional and morphologic alteration may help in developing more refined therapeutic strategies aimed to reduce the high CV burden in chronic kidney disease. The potential therapeutic interventions - mainly the use of certain antihypertensive drugs and reduction of vascular calcification - are finally discussed.
Gusbeth-Tatomir
Paul
P
Dialysis and Renal Transplantation Center, Parhon University Hospital, Iasi, Romania.
Covic
Adrian
A
D000959:Antihypertensive Agents / Q000627:therapeutic use; D001158:Arteries / Q000473:pathology* / Q000502:physiology; D050197:Atherosclerosis / Q000150:complications* / Q000209:etiology* / Q000503:physiopathology; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control; D002614:Chelating Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004548:Elasticity; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D017379:Hypertrophy, Left Ventricular / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D007674:Kidney Diseases / Q000150:complications* / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000503:physiopathology; D011073:Polyamines / Q000627:therapeutic use; D012307:Risk Factors; D000069603:Sevelamer
D000959:Antihypertensive Agents; D002614:Chelating Agents; D011073:Polyamines; D000069603:Sevelamer